Targeting IGF-1 Pathways (AugSept 2015) Townsend Letter, Alternative Medicine Magazine

From the Townsend Letter
August/September 2015

Order this issue!

Targeting the IGF-1 Pathways
by Jacob Schor, ND, FABNO

Page 1, 2, 3

Notes
1.      Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol. 2010 Nov 20;28(33):4985–4995.
2.      Salmon WD, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med. 1957 Jun;49(6):825–836.
3.      Van den Brande JL. A personal view on the early history of the insulin-like growth factors. Horm Res. 1999;51 Suppl 3:149–175.
4.      Yakar S, Courtland HW, Clemmons D. IGF-1 and bone: New discoveries from mouse models. J Bone Miner Res. 2010 Dec;25(12):2543–2552. doi:10.1002/jbmr.234.
5.      Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell. 1993 Oct 8;75(1):59–72.
6.      Sutter NB, Bustamante CD, Chase K, et al. A single IGF1 allele is a major determinant of small size in dogs. Science. 2007 Apr 6;316(5821):112–115. Erratum in: Science. 2007 Jun 1;316(5829):1284.
7.      Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol Pathol. 2001 Oct;54(5):311–316. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1187088/pdf/mp54000311.pdf
8.      Ibid.
9.      Bai N. Defective growth gene in rare dwarfism disorder stunts cancer and diabetes. Sci Am. Retrieved 17 February 2011. [Great article!] Available at http://www.scientificamerican.com/article/defective-growth-gene-in-dwarfism
10.    Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. VD. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011 Feb 16;3(70):70ra13. doi:10.1126/scitranslmed.3001845.
11.    Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm IGF Res. 2007 Feb;17(1):54–57. Epub 2006 Dec 12.
12.    Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 2002 Jul 17;94(14):1099–1106. Available at http://jnci.oxfordjournals.org/content/94/14/1099.long.
13.    Cromie WJ. Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Apridonidze T, He N, Nestler JE. J Clin Endocrinol Metab. 2004 Jan;89(1):242-9. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome.J Clin Endocrinol Metab. Growth factor raises cancer risk. Harvard University Gazette. April 22, 1999. Available at http://www.news.harvard.edu/gazette/1999/04.22/igf1.story.html.
14.    Nimptsch K, Platz EA, Pollak MN, et al. Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993–2004. Int J Cancer. 2011 Feb 1;128(3):660–667. doi:10.1002/ijc.25381. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948057.
15.    Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 2002 Jul 17;94(14):1099–1106.
16.    Wei EK, Ma J, Pollak MN, et al. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):850–855.
17.    Birmann BM, Tamimi RM, Giovannucci E, et al. Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):282–288. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661109.
18.    Kang HS, Ahn SH, Mishra SK, et al. Association of polymorphisms and haplotypes in the insulin-like growth factor 1 receptor (IGF1R) gene with the risk of breast cancer in Korean women. PLoS One. 2014 Jan 2;9(1):e84532.
19.    Kaaks R, Johnson T, Tikk K, et al. Insulin-like growth factor I and risk of breast cancer by age and hormone receptor status-A prospective study within the EPIC cohort. Int J Cancer. 2014 Jun 1;134(11):2683–2690.
20.    Cao H, Wang G, Meng L, et al. Association between circulating levels of IGF-1 and IGFBP-3 and lung cancer risk: a meta-analysis. PLoS One. 2012;7(11):e49884. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501472.
21.    Schmidt JA, Allen NE, Almquist M, et al. Insulin-like growth factor-I and risk of differentiated thyroid carcinoma in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. Epub2014 Mar 19.
22.    An excellent review: Weroha SJ, Haluska P. IGF system in cancer. Endocrinol Metab Clin North Am. 2012 June;41(2):335–350. doi:10.1016/j.ecl.2012.04.014. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614012/pdf/nihms379615.pdf
23.    Kabat GC, Anderson ML, Heo M, et al. Adult stature and risk of cancer at different anatomic sites in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1353–1363.
24.    Weroha SJ, Haluska P. The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am. 2012 Jun;41(2):335–350. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614012.
25.    Milman S, Atzmon G, Huffman DM, et al. Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell. Epub 2014 Mar 12.
26.    Renehan AG1, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004 Apr 24;363(9418):1346–1353.
27.    Renehan AG, Harvie M, Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer. 2006 Jun;13(2):273–278.
28.    Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med. 2008 Oct 7;149(7):461–471,W83–88. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584869.
29.    Duggan C, Wang CY, Neuhouser ML, et al. Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer. Int J Cancer. 2013 Mar 1;132(5):1191–1200.
30.    Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol. 2010 Nov 20;28(33):4985–4995.
31.    Nahta R. Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance. Chemother Res Pract. 2012;2012:648965.
32.    Lee JC, Jang SH, Lee KY, Kim YC. Treatment of non-small cell lung carcinoma after failure of epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Res Treat. 2013 Jun;45(2):79–85.
33.    Arnaldez FI, Helman LJ. Targeting the insulin growth factor receptor 1. Hematol Oncol Clin North Am. 2012 Jun;26(3):527–542,vii–viii. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334849.
34.    Weroha SJ, Haluska P. The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am. 2012 Jun;41(2):335–350,vi. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614012.
35.    Yang Y, Yee D. Targeting insulin and insulin-like growth factor signaling in breast cancer. J Mammary Gland Biol Neoplasia. 2012 Dec;17(3–4):251–261. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534944.
36.    Arnaldez FI, Helman LJ. Targeting the insulin growth factor receptor 1. Hematol Oncol Clin North Am. 2012 Jun;26(3):527–542,vii–viii. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334849.
37.    ClinicalTrials.gov [website].
38.    Chi KN, Gleave ME, Fazli L, et al. A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res. 2012 Jun 15;18(12):3407–3413. doi:10.1158/1078-0432.CCR-12-0482. Epub 2012 May 2.
39.    Beltran PJ, Chung YA, Moody G, et al. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther. 2011 Jun;337(3):644–654.
40.    Kindler HL, Richards DA, Garbo LE, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012 Nov;23(11):2834–2842.
41.    Rajan A, Carter CA, Berman A, et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014 Feb;15(2):191–200.
42.    Doi T, Muro K, Yoshino T, et al. Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2013 Sep;72(3):643–652.
43.    Yang Y, Yee D. Targeting insulin and insulin-like growth factor signaling in breast cancer. J Mammary Gland Biol Neoplasia. 2012 Dec;17(3–4):251–261. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534944.
44. Stenger M. Phase III trial of figitumumab plus chemotherapy in advanced NSCLC stopped early for futility and increased harm. Asco Post. September 1, 2014;5(14). Available at http://www.ascopost.com/issues/september-1,-2014/phase-iii-trial-of-figitumumab-plus-chemotherapy-in-advanced-nsclc-stopped-early-for-futility-and-increased-harm.aspx.
45.    Scagliotti GV, Bondarenko I, Blackhall F, et al. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Ann Oncol. 2015 Mar;26(3):497–504.
46.    Weroha SJ, Haluska P. The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am. 2012 Jun;41(2):335–350. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614012.
47.    Pillai RN, Ramalingam SS. Inhibition of insulin-like growth factor receptor: end of a targeted therapy? Transl Lung Cancer Res. 2013 Feb;2(1):14–22.
48.    Chen HX, Sharon E. IGF-1R as an anti-cancer target – trials and tribulations. Chin J Cancer. 2013 May;32(5):242–252.
49.    Levine ME, Suarez JA, Brandhorst S, et al. Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab. 2014 Mar 4;19(3):407–317.
50.    Milman S, Atzmon G, Huffman DM, et al. Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell. 2014;13(4):769–771.
51.    Brugts MP, van den Beld AW, Hofland LJ, van der Wansem K, van Koetsveld PM, Frystyk J, Lamberts SW, Janssen JA. Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality. J Clin Endocrinol Metab. 2008 Jul;93(7):2515–2522.
52.    Emond JA, Pierce JP, Natarajan L, et al. Risk of breast cancer recurrence associated with carbohydrate intake and tissue expression of IGF-1 receptor. Cancer Epidemiol Biomarkers Prev. Epub 2014 Apr 22.
53.    Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE. Molecular interactions of the IGF system. Cytokine Growth Factor Rev. 2005 Aug–Oct;16(4–5):421–439.
54.    Xu CX, Zhu HH, Zhu YM. Diabetes and cancer: Associations, mechanisms, and implications for medical practice. World J Diabetes. 2014 Jun 15;5(3):372–380.
55.    Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009 Oct;30(6):586–623.
56.    Singh P, Alex JM, Bast F. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Med Oncol. 2014 Jan;31(1):805.
57.    Ameri P, Canepa M, Fabbi P, et al. Vitamin D modulates the association of circulating insulin-like growth factor-1 with carotid artery intima-media thickness. Atherosclerosis. 2014 Oct;236(2):418–425.
58.    Westwood AJ, Beiser A, Decarli C, et al. Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. Neurology. 2014 Apr 4.
59.    Dong X, Chang G, Ji XF, Tao DB, Wang YX. The relationship between serum insulin-like growth factor I levels and ischemic stroke risk. PLoS One. 2014 Apr 11;9(4):e94845. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984250.
60.    Iso H, Maruyama K, Ikehara S, Yamagishi K, Tamakoshi A. Cellular growth factors in relation to mortality from cardiovascular disease in middle-aged Japanese: the JACC study. Atherosclerosis. 2012 Sep;224(1):154–160.
61.    Westwood AJ, Beiser A, Decarli C, et al. Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. Neurology. 2014 Apr 4.
62.    Chin KY, Ima-Nirwana S, Mohamed IN, et al. Insulin-like growth factor-1 is a mediator of age-related decline of bone health status in men. Aging Male. 2014 Mar 5.
63.    Couzin J. Can fasting blunt chemotherapy's debilitating side effects? Science. 29 August 2008.
64.    Lee C, Raffaghello L, Brandhorst S, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012 Feb 8.
65.    Redman LM1, Veldhuis JD, Rood J, Smith SR, Williamson D, Ravussin E; Pennington CALERIE Team. The effect of caloric restriction interventions on growth hormone secretion in nonobese men and women. Aging Cell. 2010 Feb;9(1):32–39. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807912.
66.    Kari FW, Dunn SE, French JE, Barrett JC. Roles for insulin-like growth factor-1 in mediating the anti-carcinogenic effects of caloric restriction. J Nutr Health Aging. 1999;3(2):92–101.
67.    Wright JL, Plymate S, D'Oria-Cameron A, et al. A study of caloric restriction versus standard diet in overweight men with newly diagnosed prostate cancer: a randomized controlled trial. Prostate. 2013 Sep;73(12):1345–1351.
68.    Michaelsen KF, Greer FR. Protein needs early in life and long-term health. Am J Clin Nutr. 2014 Mar;99(3):718S–722S.
69.    Fontana L, Weiss EP, Villareal DT, Klein S, Holloszy JO. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. Aging Cell. 2008 Oct;7(5):681–687.
70.    Henning PC, Margolis LM, McClung JP, Young AJ, Pasiakos SM. High protein diets do not attenuate decrements in testosterone and IGF-I during energy deficit. Metabolism. 2014 May;63(5):628–632.
71.    Vasto S, Buscemi S, Barera A, Di Carlo M, Accardi G, Caruso C. Mediterranean diet and healthy ageing: a Sicilian perspective. Gerontology. 2014 Aug 23.
72.    Qin LQ, He K, Xu JY. Milk consumption and circulating insulin-like growth factor-I level: a systematic literature review. Int J Food Sci Nutr. 2009;60 Suppl 7:330–340.
73.    Zhu K, Meng X, Kerr DA, et al. The effects of a two-year randomized, controlled trial of whey protein supplementation on bone structure, IGF-1, and urinary calcium excretion in older postmenopausal women. J Bone Miner Res. 2011 Sep;26(9):2298–2306.
74.    Xu CX, Zhu HH, Zhu YM. Diabetes and cancer: Associations, mechanisms, and implications for medical practice. World J Diabetes. 2014 Jun 15;5(3):372–380.
75.    Chin KY, Ima-Nirwana S, Mohamed IN, et al. Insulin-like growth factor-1 is a mediator of age-related decline of bone health status in men. Aging Male. 2014 Mar 5.
76.    Arjmandi BH, Khalil DA, Lucas EA, et al. Dried plums improve indices of bone formation in postmenopausal women. J Womens Health Gend Based Med. 2002 Jan–Feb;11(1):61–68.
77.    Franklin M, Bu SY, Lerner MR, et al. Dried plum prevents bone loss in a male osteoporosis model via IGF-I and the RANK pathway. Bone. 2006 Dec;39(6):1331–1342.
78.    Ameri P, Giusti A, Boschetti M, et al. Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency. Eur J Endocrinol. 2013 Oct 21;169(6):767–772.
79.    Maggio M, Lauretani F, De Vita F, et al. Relationship between use of proton pump inhibitors and igf system in older subjects. J Nutr Health Aging. 2014;18(4):420–423.
80.    Hallberg LM, Ikeno Y, Englander E, Greeley GH Jr. Effects of aging and caloric restriction on IGF-I, IGF-I receptor, IGFBP-3 and IGFBP-4 gene expression in the rat stomach and colon. Regul Pept. 2000 May 10;89(1–3):37–44.
81.    Larnkjær A, Arnberg K, Michaelsen KF, Jensen SM, Mølgaard C. Effect of milk proteins on linear growth and IGF variables in overweight adolescents. Growth Horm IGF Res. 2014 Apr–Jun;24(2–3):54–59.
82.    Vasto S, Buscemi S, Barera A, Di Carlo M, Accardi G, Caruso C. Mediterranean diet and healthy ageing: a Sicilian perspective. Gerontology. 2014;60(6):508–518.
83.    Maggio M, Lauretani F, De Vita F, et al. Relationship between use of proton pump inhibitors and IGF system in older subjects. J Nutr Health Aging. 2014 Apr;18(4):420–423.
84.    Ku HC, Tsuei YW, Kao CC, et al. Green tea (-)-epigallocatechin gallate suppresses IGF-I and IGF-II stimulation of 3T3-L1 adipocyte glucose uptake via the glucose transporter 4, but not glucose transporter 1 pathway. Gen Comp Endocrinol. 2014 Apr 1;199:46–55.
85.    Laskov I, Drudi L, Beauchamp MC, et al. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol. 2014 Sep;134(3):607–614.
86.    Xia Y, Jin L, Zhang B, Xue H, Li Q, Xu Y. The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life Sci. 2007 May 16;80(23):2161–2169. Epub 2007 Apr 21.
87.    Dong X, Chang G, Ji XF, Tao DB, Wang YX. The relationship between serum insulin-like growth factor I levels and ischemic stroke risk. PLoS One. 2014 Apr 11;9(4):e94845. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984250.
88.    Ibid.
89.    Iso H, Maruyama K, Ikehara S, Yamagishi K, Tamakoshi A. Cellular growth factors in relation to mortality from cardiovascular disease in middle-aged Japanese: the JACC study. Atherosclerosis. 2012 Sep;224(1):154–160.
90.    Westwood AJ, Beiser A, Decarli C, et al. Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. Neurology. 2014 Apr 4.
91.    Chin KY, Ima-Nirwana S, Mohamed IN, et al. Insulin-like growth factor-1 is a mediator of age-related decline of bone health status in men. Aging Male. 2014 Mar 5.
92.    Bu SY, Hunt TS, Smith BJ. Dried plum polyphenols attenuate the detrimental effects of TNF-alpha on osteoblast function coincident with up-regulation of Runx2, Osterix and IGF-I. J Nutr Biochem. 2009 Jan;20(1):35–44.
93.    Cox HD, Eichner D. Detection of human insulin-like growth factor-1 in deer antler velvet supplements. Rapid Commun Mass Spectrom. 2013 Oct 15;27(19):2170–2178.
94.    Giovannucci E, Pollak M, Liu Y, et al. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):84–89.
95.    Del Vesco AP, Gasparino E, Zancanela V, et al. Acute heat stress and dietary methionine effects on IGF-I, GHR, and UCP mRNA expression in liver and muscle of quails. Genet Mol Res. 2014 Feb 13;13(3):7294–7303.
96.    Larnkjær A, Arnberg K, Michaelsen KF, Jensen SM, Mølgaard C. Effect of milk proteins on linear growth and IGF variables in overweight adolescents. Growth Horm IGF Res. 2014 Apr–Jun;24(2–3):54–59.

Page 1, 2, 3

Consult your doctor before using any of the treatments found within this site.

Subscriptions are available for Townsend Letter, the Examiner of Alternative Medicine
magazine, which is published 10 times each year. Search our pre-2001 archives for further information. Older issues of the printed magazine are also indexed for your convenience.
1983-2001 indices ; recent indices. Once you find the magazines you'd like to order, please
use our convenient form, e-mail subscriptions@townsendletter.com, or call 360.385.6021.

360.385.6021
Fax: 360.385.0699
info@townsendletter.com